

(1390 REV. 5-93) US DEPT. OF COMMERCE PATENT & TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 111487
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (if known, sec 37 C.F.R.1.5) <div style="font-size: 24pt; text-align: center;">10/018133</div>
INTERNATIONAL APPLICATION NO. PCT/FR00/01851	INTERNATIONAL FILING DATE June 30, 2000	PRIORITY DATE CLAIMED July 16, 1999
TITLE OF INVENTION NEEDLELESS SYRINGE HAVING AN INJECTOR OF FITTED-TOGETHER ELEMENTS		
APPLICANT(S) FOR DO/EO/US Alain NAVELIER, Patrick ALEXANDRE, Bernard BROUQUIERES, Claude MIKLER		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input checked="" type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 		
Items 11. to 16. below concern other document(s) or information included:		
<ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> Entitlement to small entity status is hereby asserted. 16. <input type="checkbox"/> Other items or information: 		

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) 10/018133		INTERNATIONAL APPLICATION NO. PCT/FR00/01851		ATTORNEY'S DOCKET NUMBER 111487	
---	--	--	--	---------------------------------	--

17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO\$890.00 International preliminary examination fee paid to USPTO (37 CFR1.482)\$710.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))\$740.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO\$1,040.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)\$ 100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =	CALCULATIONS	PTO USE ONLY

Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
Claims	Number Filed	Number Extra	Rate		
Total Claims	12- 20 =	0	X \$ 18.00	\$	
Independent Claims	2- 3 =	0	X \$ 84.00	\$	
Multiple dependent claim(s)(if applicable)			+ \$280.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$890.00	
Reduction by 1/2 for filing by small entity, if applicable.				-	\$
SUBTOTAL =				\$890.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 month from the earliest claimed priority date (37 CFR 1.492(f)).				+	\$
TOTAL NATIONAL FEE =				\$890.00	
				Amount to be refunded	\$
				Charged	\$


a. ☒ Check No. 126069 in the amount of \$890.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 15-0461. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
 OLIFF & BERRIDGE, PLC
 P.O. Box 19928
 Alexandria, Virginia 22320


 NAME: William P. Berridge
 REGISTRATION NUMBER: 30,024

Date: December 18, 2001

NAME: Joel S. Armstrong
 REGISTRATION NUMBER: 36,430

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Alain NAVELIER, Patrick ALEXANDRE, Bernard
BROUQUIERES, Claude MIKLER

Application No.: New National Stage of PCT/FR00/01851

Filed: December 18, 2001

Docket No.: 111487

For: NEEDLELESS SYRINGE HAVING AN INJECTOR OF FITTED-TOGETHER
ELEMENTS

PRELIMINARY AMENDMENT

Director of the U.S. Patent and Trademark Office
Washington, D. C. 20231

Sir:

Prior to initial examination, and after entry of Annexes to the IPER, please amend the
above-identified application as follows:

IN THE CLAIMS:

Please replace claims 4-11 as follows:

4. (Amended) The needless syringe as claimed in claim 1, characterized in that
the groove (31, 41, 41') is straight.
5. (Amended) The needless syringe as claimed in claim 1, characterized in that
the groove is helical.
6. (Amended) The needless syringe as claimed in claim 1, characterized in that a
groove (54) is formed by the convergence of at least two grooves beginning from the
upstream face and ending in a single groove towards the downstream face of the element
(34).
7. (Amended) The syringe as claimed in claim 4, characterized in that the groove
(31, 41, 41') has a constant cross section.
8. (Amended) The syringe as claimed in claim 4, characterized in that the groove
(53, 54, 55) has an evolving cross section.

9. (Amended) The needleless syringe as claimed in claim 1, characterized in that the injector (1) includes a support (4) comprising a housing into which a one-piece core (3, 33, 34) is fitted.

10. (Amended) The needleless syringe as claimed in claim 1, characterized in that the injector comprises at least one core consisting of at least two quarters assembled via their flat faces to form at least one core with a nozzle of evolving cross section, the quarters of the various cores being fitted into housings of a support.


11. (Amended) The needleless syringe as claimed in claim 1, characterized in that the injector (10) comprises at least one core consisting of at least two quarters (5, 6) assembled by their flat faces (50, 60) to form at least one core with a nozzle (55) with an evolving cross section, the quarters (5, 6) of the various cores being held together by overmolding (45).

REMARKS

Claims 1 - 11 are pending. By this Preliminary Amendment, claims 4-11 are amended to remove multiple dependencies. Prompt and favorable examination on the merits is respectfully requested.

The attached Appendix includes marked-up copies of each rewritten claim (37 C.F.R. 1.121(c)(1)(ii)).

Respectfully submitted,


William P. Berridge
Registration No. 30,024

Joel S. Armstrong
Registration No. 36,430

WPB:JSA/mlb
Attached: Appendix
Date: December 18, 2001

OLIFF & BERRIDGE, PLC
P.O. Box 19928
Alexandria, Virginia 22320
Telephone: (703) 836-6400

DEPOSIT ACCOUNT USE AUTHORIZATION Please grant any extension necessary for entry; Charge any fee due to our Deposit Account No. 15-0461
--

APPENDIX

Changes to Claims:

The following are marked-up versions of the amended claims:

4. ~~(Amended)~~ The needleless syringe as claimed in claim 1 ~~one of claims 1, 2 and 3~~, characterized in that the groove (31, 41, 41') is straight.
5. ~~(Amended)~~ The needleless syringe as claimed in claim 1 ~~one of claims 1 and 2~~, characterized in that the groove is helical.
6. ~~(Amended)~~ The needleless syringe as claimed in claim 1 ~~one of claims 1, 2 and 3~~, characterized in that a groove (54) is formed by the convergence of at least two grooves beginning from the upstream face and ending in a single groove towards the downstream face of the element (34).
7. ~~(Amended)~~ The syringe as claimed in claim 4 ~~one of claims 4, 5 and 6~~, characterized in that the groove (31, 41, 41') has a constant cross section.
8. ~~(Amended)~~ The syringe as claimed in claim 4 ~~one of claims 4, 5 and 6~~, characterized in that the groove (53, 54, 55) has an evolving cross section.
9. ~~(Amended)~~ The needleless syringe as claimed in claim 1 ~~one of claims 1, 2, 3 and 8~~, characterized in that the injector (1) includes a support (4) comprising a housing into which a one-piece core (3, 33, 34) is fitted.
10. ~~(Amended)~~ The needleless syringe as claimed in claim 1 ~~one of claims 1, 3 and 8~~, characterized in that the injector comprises at least one core consisting of at least two quarters assembled via their flat faces to form at least one core with a nozzle of evolving cross section, the quarters of the various cores being fitted into housings of a support.
11. ~~(Amended)~~ The needleless syringe as claimed in claim 1 ~~one of claims 1, 2, 3 and 8~~, characterized in that the injector (10) comprises at least one core consisting of at least two quarters (5, 6) assembled by their flat faces (50, 60) to form at least one core with a

nozzle (55) with an evolving cross section, the quarters (5, 6) of the various cores being held together by overmolding (45).

ABSTRACT OF THE DISCLOSURE

The invention concerns the field of needleless syringes for injecting an active principle for therapeutic purposes. More particularly, it concerns a needleless syringe for injecting an active principle (7) initially set between an injector (1, 10) comprising at least an injection nozzle, said injector being contacted with the skin, and a wall (8) mobile under the effect of a propelling system (9) pressurizing and expelling the active principle through the injector located at the syringe downstream end (2). In order to produce nozzles in a considerable injector thickness and to control the jet coherence distance, said injector (1, 10) comprises at least two elements (3, 4) whereof the contact surfaces (30, 40, 40') are oriented towards the skin, at least a groove (31, 41, 41') forming an injection nozzle in the assembly of said elements.

WO 01/05454

- 1 -

PCT/FR00/01857

NEEDLELESS SYRINGE HAVING AN INJECTOR OF FITTED-
TOGETHER ELEMENTS

The present invention is in the field of needleless
5 syringes used for intradermic, subcutaneous and
intramuscular injections of liquid active principle for
therapeutic use in human or veterinary medicine.

In this field, to improve the effectiveness of the
10 injection, use is made of syringes with, at their
downstream part applied to the skin or very close to
the skin of the subject, an injector comprising several
ducts so that the liquid that is to be injected can be
distributed to several points spread over a relatively
15 large area. This solution also has the advantage of
reducing the pain and eliminating any possible
superficial or subcutaneous damage that might result
from an excessive amount of liquid injected at a single
point.

20

To improve the effectiveness of the injection, the
shape of the jet is also altered: the coherent distance
of the jet is controlled and a solution is sought that
is somehow between a highly coherent jet, such as used
25 for jet cutting and which would have very deep
penetration and would cause dangerous tearing of the

skin, and a jet which nebulizes the liquid and thus the fine droplets do not penetrate the skin.

US patent 3 802 430 describes a needleless syringe in
5 which the liquid that is to be injected is discharged
by a piston pushed by gases produced by a pyrotechnic
generator; that syringe has five ducts which are
parallel to the axis of the syringe and have circular
cross sections. US patent 3 788 315 describes a syringe
10 in which the piston discharging the liquid is pushed by
the expansion of compressed gases or of a compressed
spring. That syringe has six ducts of circular cross
sections and the axes of which diverge slightly from
the axis of the syringe. In these examples, although
15 the liquid is spread across several points, the ducts
remain fairly close together; in addition, the
simplicity of the shape of these ducts shows that these
ducts are not optimized for controlling the coherent
length of the jet which is itself an important factor
20 in the performance of the injector in this particular
application.

More generally, the problems posed by producing an
injector for a syringe are problems of mechanical

strength, of performance as we have just mentioned, and of cost.

Specifically, the injector, placed at the downstream
5 part of the syringe, must not deform under the effect
of the pressure of the liquid at the time of injection:
the injector has to be relatively thick, and the more
widely the ducts are spread over a large area, the
thicker it has to be. The problem will be that of
10 producing ducts which in general are very fine through
great thicknesses.

The performance of the injector lies in the possibility
of controlling the coherent distance of the jets
15 leaving the ducts or nozzles, for predetermined
conditions of use (nature of the liquid, injection
pressure), through ducts of appropriate cross sections.
The purpose of this appropriate cross section is to
create a field of turbulence in the flow such that, a
20 short distance from the exit from the injector, the jet
remains coherent, that is to say is fine and fast-
moving enough to pierce and penetrate the skin of the
subject that is to be treated, and then the jet very
quickly loses its coherency: it explodes to best
25 diffuse the active principle under the skin. The

problem is that of, in a simple way, producing not only fine ducts over great thicknesses but, above all, ducts with appropriate cross sections.

- 5 Finally, the cost of manufacture becomes a very important factor in the case of mass-produced syringes, particularly for disposable syringes.

10 The present invention relates to a needleless syringe for intradermic, subcutaneous or intramuscular injecting of a liquid active principle initially placed between, on the one hand, an injector comprising at least one injection nozzle, said injector being placed in contact with the skin or a very short distance away
15 from the skin of the subject that is to be treated, and, on the other hand, a wall that can be displaced under the effect of a propulsive system pressurizing and expelling the active principle through the injector placed at the downstream end of the syringe, which is
20 such that the injector consists of at least two elements the contacting surfaces of which are directed towards the skin, at least one of the contacting surfaces having at least one groove which constitutes an injection nozzle in the assembly of said elements.

In this invention, "liquid active principle" is essentially intended to mean a somewhat viscous liquid, or a mixture of liquids, or a gel. The active principle may be a solid placed in solution in an appropriate solvent for injection. The active principle may be a solid in pulverulent form placed in suspension, of greater or lesser concentration, in an appropriate liquid. The particle size of the solid active principle and the shape of the duct need to be matched to avoid the ducts becoming blocked.

One constituent element of the injector comprises a face which lies on the active principle side: this will be termed the upstream face, and a face located on the skin side: this will be termed the downstream face, and the lateral surface, all or some of which is in contact with all or some of the lateral surface of at least one other element. Over at least a portion of the lateral surface, at least one groove runs from the upstream face to the downstream face.

In the assembly of the constituent elements a groove may face the lateral surface of an adjacent element; it may also face another groove running along the lateral face of the other adjacent element; the grooves placed

facing each other may have identical or different cross sections.

In the case of the injector of the syringe in a first configuration, the contacting surfaces of two adjacent elements, which contacting surfaces are wholly or partly lateral surfaces of said elements, are surfaces of revolution.

10 In a second configuration of the injector, the contacting surfaces of two adjacent elements, which contacting surfaces are wholly or partly lateral surfaces of said elements, are flat surfaces.

15 The transverse dimensions of a groove are very small with respect to the length of the groove. It may be said to a first approximation that the groove is positioned around the curve running along a portion of the lateral surface of a constituent element of the
20 injector.

In a first embodiment, this curve running along the lateral face is roughly straight: the groove will be said to be straight. This is, for example, the case of

a longitudinal groove made on a surface which is itself flat, or cylindrical or conical.

In a second embodiment, this curve running along the lateral face is not straight or is an oblique curve not contained in any plane, and the groove will be said to be helical. This is, for example, the case of a helical groove produced on a cylindrical or conical surface.

10 In a third embodiment, this groove is formed by the convergence of at least two groove portions beginning from the upstream face of the element and ending in a single groove portion towards the downstream face of the element. The various groove portions are straight
15 or helical.

Advantageously, the groove has a cross section that is roughly constant when following the groove from the upstream face to the downstream face of the element.
20 Its cross section is preferably of simple geometric shape, for example a V-shaped, U-shaped or semicircular groove. These shapes have a plane of symmetry which passes through an axis of symmetry of the element.

As a preference, the groove has an evolving cross section. When the groove is followed from the upstream face to the downstream face, its cross section varies or evolves, increasing or decreasing, uniformly or abruptly, so that the nozzle has a succession of tubular parts and of cavities, an appropriate arrangement of these various parts making it possible to master and control the jet coherent distance according to predetermined conditions of use: viscosity of the liquid that is to be injected, injection pressure, in particular.

Such an evolving cross section is, for example, achieved simply from a groove of constant cross section, like the one previously described, on which is superposed at least one recess which locally widens and deepens the groove. In the assembly of the elements of the injector, said recesses will create cavities along the injection nozzle which will be of evolving cross section, this arrangement making it possible to control the jet coherent distance.

The convergence of at least two grooves into a single groove may also achieve the evolving cross section as it is to be understood here.

Finally, the groove may be a succession of recesses very close together which constitute the groove of evolving cross section.

5

In a first embodiment of the needleless syringe, the injector includes a support comprising at least one housing into which an element which constitutes a one-piece core is fitted. Said core and support comprising
10 grooves to produce at least one injection nozzle.

In the second embodiment of the needleless syringe, the injector comprises at least one core consisting of at least two elements or quarters assembled via their flat
15 faces to form at least one nozzle of evolving cross section, the elements or quarters of the various cores being fitted into housings of a support.

For these two embodiments, a fitting-together is
20 preferably a forced press fit which also ensures sealing at the contacting surfaces.

The one-piece core or the core made up of several quarters either exhibit symmetry of revolution; the
25 core has the shape of a cylinder or of a cone frustum,

or symmetry of repetition of order n: the core has the shape of a prism or of a pyramid frustum. Obviously, the housing that accommodates the core has the same shape, it has a mating shape so that the two can be
5 fitted together.

In a third embodiment of the needleless syringe, the injector comprises at least one core consisting of at least two quarters assembled by their flat faces to
10 form at least one nozzle with an evolving cross section, the quarters of the various cores being held together by overmolding.

Nested assemblies, in which a subassembly comprising a support of overmolding equipped with their cores also
15 forms part of the invention. The preferred nested assembly is the one that consists of the fitting-together of a core into a support having one single housing, this fitted-together assembly acting as a core
20 for another support with one single housing. One particularly simple embodiment consists in fitting a core directly into the downstream end of the syringe formed for this purpose.

Advantageously, in the case of elements of truncated shape such as cone frustums, pyramid frustums or quarters of such elements, construction and assembly will be performed in such a way that the downstream
5 face is that of the smallest cross section: through this assembly, the pressure of the liquid will have a tendency to fit the elements together rather than driving them out of their housings.

- 10 The present invention also relates to an injector such that said injector consists of at least two elements the contacting surfaces of which are directed towards the skin, at least one of the contacting surfaces comprising at least one groove which constitutes an
15 injection nozzle in the assembly of said elements.

A syringe according to the invention solves the problems posed. In terms of the strength of the injector, the increase in the thickness presents no
20 difficulties with regard to producing fine ducts with evolving or non-evolving cross sections over great thicknesses.

In terms of the performance of the injector, the
25 invention makes it possible in a simple way, in order

so that it can be adapted to predetermined conditions of use, to control the coherence distance of the jets leaving the nozzles.

5 In terms of the cost aspect, the injector has relatively simple shapes which are easy to produce, by directly molding the elements of the injector or by machining grooves and recesses into blanks produced elsewhere. All of these manufacturing and assembly
10 operations lend themselves to a high degree of automation.

The syringe according to the invention additionally has an undeniable advantage from the point of view of
15 safety in the event of abnormal use. For example, if the syringe is directed towards the face and triggered accidentally, the jets will have no effect other than to shower said face with active principle, without any mechanical piercing effect, as long as the syringe is
20 not in contact with (or very close to) the face. This advantage is associated with the mastery of the jet coherence distance.

The present invention will be described in greater
25 detail with the aid of the following figures.

Figure 1 depicts, in longitudinal part section, a syringe according to the invention.

5 Figure 2 depicts, in cross section, the injector of said syringe.

Figures 3 and 4 depict, in perspective, types of cores that can be used in the injector of the syringe
10 previously depicted.

Figure 5 depicts, viewed in perspective, two elements of a core according to another embodiment of the invention.

15

Figure 6 depicts, in longitudinal section, a syringe injector obtained by assembling elements of the type of those depicted in figure 5.

20 Figure 1 schematically depicts a needleless syringe for injecting liquid active principle. Such a syringe is generally cylindrical and has a reservoir containing the active principle 7. This reservoir is closed at one end, which we have called the downstream end 2, by an
25 injector 1 comprising at least one duct or one

injection nozzle. This injector generally rests against the skin of the subject that is to be treated, or is held a very short distance away from the skin, the skin not being depicted in this drawing. This injector is the end of the reservoir or is an attached piece 3, fixed to this end of the reservoir by appropriate means. The other end of the reservoir is closed by a displaceable wall, for example a piston 8 comprising means for providing sealing, such as an O-ring.

10 Finally, the syringe comprises a propulsive system 9 with a triggering device for displacing the piston and injecting the liquid. Among the propulsive systems that can be used and without going into detail thereof, we may mention a pyrotechnic gas generator as described in

15 US patent 3 802 430 already mentioned, we also mention the expansion of a compressed gas or the compressed spring, as described in US patent 3 788 315. Obviously, the syringes according to the invention may be fitted with any one of these types of propulsion system for

20 displacing the piston.

The injector 1 (see also Fig. 2) is forcibly press fitted into the end 2 of the syringe. This injector comprises an essentially cylindrical support 4 with an

25 exterior lateral face 40 resting against the interior

lateral face 20 of the end of the syringe and an interior lateral face 40' against which the exterior lateral face 30 of a core 3, in this example a one-piece core, comes into contact. The support 4 and the core 3 each have, on the upstream side, a shoulder which serves to immobilize and wedge these three elements 3 and 4 in the assembly; the shoulder is, in this example, frustoconical. The grooves on the exterior lateral walls continue into the frustoconical shoulder.

Figure 2 depicts, in cross section, the downstream end 2 of the previously described syringe. The support 4 is fitted into the end 2 of the syringe, the contacting faces being, respectively, the lateral faces 40 and 20'. Fitted inside the support 4 is a core 3, the contacting faces being, respectively, the lateral faces 40' and 30. The exterior lateral face 40 of the support 4 has four grooves, such as the groove 41, and these are uniformly distributed and have roughly the shape of a semicircle, said grooves facing the lateral surface 20 of the downstream end 2 of the syringe. The interior lateral face 40' of the support 4 also comprises four grooves, such as the groove 41', similar to the previous ones, also uniformly distributed but offset by

45° with respect to the outer grooves. Finally, the lateral face 30 of the core 3 has eight grooves, such as the groove 31, these being uniformly distributed and having a V-shaped cross section. Of these grooves, every second one faces a groove such as the groove 41', the other grooves facing the interior lateral wall 40' of the support.

The grooves on the exterior lateral walls, grooves such as the grooves 31 or 41, continuing to the frustoconical shoulder of the core 3 and of the support 4. The grooves on an interior lateral face such as the groove 41' are in the continuation of the opening in the shoulder of the groove such as 31 placed facing it.

The transverse dimensions of the grooves are such that they correspond to circular orifices with equivalent diameters of 0.05 mm to 0.5 mm. The height of an element injector is between about 3 mm and about 10 mm. Finally, the orifices of the grooves are distributed around concentric circles, the diameters of which are between 3 mm and 30 mm.

Figure 3 depicts a core 33 viewed in perspective. This core is mounted on a support of the type depicted in the previous figures.

5 The core 33 is essentially circular and cylindrical, and on the upstream side has a frustoconical shoulder, the upstream face 331 of which is visible. The lateral surface of the core has eight grooves 53 distributed uniformly, these are longitudinal and of semicircular
10 cross section; these grooves continue into the shoulder. On each groove there are two conical recesses 63 which locally widen and deepen the groove. When this core is fitted into a housing of a support, these grooves and recesses will produce a nozzle of evolving
15 cross section comprising, in this example, two cavities which will generate turbulence in the jet and thus allow the jet coherence distance to be controlled.

In this example, the core, over a circular part, has a
20 diameter of 8 mm and its overall height (including shoulder) is 5.8 mm; the grooves are of semicylindrical shape, the radius being 0.1 mm, the cones having the vertex angle of 90° and a circular base 1 mm in diameter.

Figure 4 depicts another core 34 viewed in perspective.

This core, the geometry of which is of revolution, is the combination of the frustoconical part at the upstream end and of a cylindrical part at the downstream end, this combination of shapes ensuring that the core is self-immobilized in its housing. The lateral surface 340 of the core has eight groups of uniformly distributed grooves. The cross section of the grooves is U-shaped. On the frustoconical part of the lateral surface 340, starting from the upstream face 341, two identical groove portions converge to join together as a single groove, with the same cross section on the cylindrical part of the lateral surface so as to open onto the downstream face. In this example, the shear at the confluence of two flows will generate the turbulence that controls the jet coherence distance.

Figure 5 depicts, in perspective, a core consisting of several parts or quarters, in this example two parts 5 and 6 essentially in the shape of two half-cylinders depicted with a marked separation to make the diagram more legible. These two half-cylinders 5 and 6 will be back to back via their flat faces 50 and 60 (the latter

is hidden in the case of the element 6). In this example, each flat face has, at its middle, a groove of evolving cross section. Given that its appearance differs slightly from what has already been described, 5 we shall also call it a recess, but said recess is really a groove with evolving cross section according to the invention.

Figure 6 depicts, in cross section, an injector 10 consisting of two cores comprising two parts 5, 6 assembled in an overmolding 45; the parts 5, 6 have, at their two ends, a portion of smaller diameter which forms shoulders for centering the elements in the overmolding. In the assembly of the quarters such as 5 15 and 6, the recesses facing each other form a duct 55 with symmetry of revolution and evolving cross section comprising, in this example, from the upstream face to the downstream face, a cone frustum meeting an oblong cavity followed by a circular cylindrical portion 20 connecting to a cavity formed by two unequal cone frustums joined by their largest bases.

In general, the thickness of an element of the injector, this being the distance from the upstream 25 face to the downstream face, is between about 3 mm and

about 10 mm. The dimensions of the cross sections of the grooves or the recesses evolve and are such that the area corresponds to that of a circular duct of a diameter varying between about 50 μm and 1000 μm .

5

The materials for producing the syringe and the various parts of the nozzle will be chosen from materials which are compatible and approved for medical use; without claiming to be exhaustive, we quote by way of example

10 plastics materials such as polycarbonate, polytetrafluoroethylenes; metals, stainless steel, or glass for medical use type I or II.

Claims

1. A needleless syringe for injecting an active principle (7) initially placed between, on the one hand, an injector (1, 10) comprising at least one injection nozzle, said injector being placed at the downstream end (2) of the syringe, and, on the other hand, a wall (8) that can be displaced under the effect of a propulsive system (9) pressurizing and expelling the active principle through the injector, characterized in that the injector (1, 10) consists of the assembly of at least two elements (3, 4, 5, 6, 33, 34); each element having a downstream face, an upstream face and a lateral surface joining them together, the contacting surfaces (30, 40, 40', 50, 60, 330, 340) of said elements in the assembly being wholly or partly lateral surfaces of said elements; at least one of the contacting surfaces having at least one groove (31, 41, 41', 53, 54, 55) which constitutes an injection nozzle in the assembly of said elements.
2. The needleless syringe as claimed in claim 1, characterized in that the contacting surfaces (30, 40, 40') are surfaces of revolution.

3. The needleless syringe as claimed in claim 1, characterized in that the contacting surfaces (50, 60) are flat surfaces.
- 5 4. The needleless syringe as claimed in one of claims 1, 2 and 3, characterized in that the groove (31, 41, 41') is straight.
- 10 5. The needleless syringe as claimed in one of claims 1 and 2, characterized in that the groove is helical.
- 15 6. The needleless syringe as claimed in one of claims 1, 2 and 3, characterized in that a groove (54) is formed by the convergence of at least two grooves beginning from the upstream face and ending in a single groove towards the downstream face of the element (34).
- 20 7. The syringe as claimed in one of claims 4, 5 and 6, characterized in that the groove (31, 41, 41') has a constant cross section.

8. The syringe as claimed in one of claims 4, 5 and 6, characterized in that the groove (53, 54, 55) has an evolving cross section.

5 9. The needleless syringe as claimed in one of claims 1, 2, 3 and 8, characterized in that the injector (1) includes a support (4) comprising a housing into which a one-piece core (3, 33, 34) is fitted.

10 10. The needleless syringe as claimed in one of claims 1, 3 and 8, characterized in that the injector comprises at least one core consisting of at least two quarters assembled via their flat faces to form at least one core with a nozzle of evolving
15 cross section, the quarters of the various cores being fitted into housings of a support.

11. The needleless syringe as claimed in one of claims 1, 2, 3 and 8, characterized in that the injector
20 (10) comprises at least one core consisting of at least two quarters (5, 6) assembled by their flat faces (50, 60) to form at least one core with a nozzle (55) with an evolving cross section, the quarters (5, 6) of the various cores being held
25 together by overmolding (45).

12. An injector (1, 10) for a needleless syringe,
characterized in that said injector consists of at
least two elements (3, 4, 5, 6, 30, 33, 34); each
element having a downstream face parallel to the
5 downstream face of the injector, an upstream face and a
lateral surface joining them together, the contacting
surfaces (30, 40, 40', 50, 60, 330, 340) of said
elements in the assembly being wholly or partly lateral
surfaces of said elements; at least one of the
10 contacting surfaces comprising at least one groove (31,
41, 41', 53, 54, 55) which constitutes an injection
nozzle in the assembly of said elements.




FIG.1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6

**DECLARATION AND POWER OF ATTORNEY
UNDER 35 USC §371(c)(4) FOR
PCT APPLICATION FOR UNITED STATES PATENT**

As a below named inventor, I hereby declare that:
my residence, post office address and citizenship are as stated below under my name;

I verily believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought, namely the invention entitled: Needleless syringe having an injector of fitted-together elements

described and claimed in international application number PCT/FR00/01851 filed on June 30, 2000

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations §1.56.

Under Title 35, U.S. Code §119, the priority benefits of the following foreign application(s) filed within one year prior to my international application are hereby claimed:

The following application(s) for patent or inventor's certificate on this invention were filed in countries foreign to the United States of America either (a) more than one year prior to my international application, or (b) before the filing date of the above-named foreign priority application(s):

FR 99 09252 filed on July 16, 1999

I hereby appoint the following as my attorneys of record with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office:

James A. Oliff, Reg. No. 27,075; William P. Berridge, Reg. No. 30,024;
Kirk M. Hudson, Reg. No. 27,562; Thomas J. Pardini, Reg. No. 30,411;
Edward P. Walker, Reg. No. 31,450; Robert A. Miller, Reg. No. 32,771;
Mario A. Costantino, Reg. No. 33,565; and Caroline D. Dennison, Reg. No. 34,494.

ALL CORRESPONDENCE IN CONNECTION WITH THIS APPLICATION SHOULD BE SENT TO OLIFF & BERRIDGE, PLC, P.O. BOX 19928, ALEXANDRIA, VIRGINIA 22320, TELEPHONE (703) 836-6400.

I hereby declare that I have reviewed and understand the contents of this Declaration, and that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1	Typewritten Full Name of Sole or First Inventor	<u>Alain</u> <u>NAVELIER</u>		
		Given Name	Middle Initial	Family Name
2	Inventor's Signature	<u>[Signature]</u>		
3	Date of Signature	<u>June</u>	<u>14</u>	<u>2001</u>
		Month	Day	Year
	Residence:	<u>PIERREFEU DU VAR</u>		
		City	State or Province	Country
	Citizenship:	<u>FRANCE</u>		
	Post Office Address: (Insert complete mailing address, including country)	<u>Quartier Figou</u> <u>83390 PIERREFEU DU VAR - FRANCE</u>		

Note to Inventor: Please sign name on line 2 exactly as it appears in line 1 and insert the actual date of signing on line 3.

PAGE 2 OF U.S.A. DECLARATION FORM
(Discard this page in a sole inventor application)

1 **Typewritten Full Name** 2-00
of Second Joint Inventor (if any) Patrick ALEXANDRE
Given Name Middle Initial Family Name

2 ****Inventor's Signature:** [Signature]

3 ****Date of Signature:** June 14 2001
Month Day Year

Residence: GRAY
City State or Province Country

Citizenship: FRANCE

Post Office Address:
(Insert complete mailing address, including country) 14, avenue de la Libération
70100 GRAY - FRANCE

1 **Typewritten Full Name** 3-00
of Third Joint Inventor (if any) Bernard BROQUIERES
Given Name Middle Initial Family Name

2 ****Inventor's Signature:** [Signature]

3 ****Date of Signature:** June 26 2001
Month Day Year

Residence: TOULON
City State or Province Country

Citizenship: FRANCE FRX

Post Office Address:
(Insert complete mailing address, including country) 4, rue Sandin
83100 TOULON - FRANCE

1 **Typewritten Full Name** 4-00
of Fourth Joint Inventor (if any) Claude MIKLER
Given Name Middle Initial Family Name

2 ****Inventor's Signature:** Claude

3 ****Date of Signature:** July 16 2001
Month Day Year

Residence: DIJON
City State or Province Country

Citizenship: FRANCE FRX

Post Office Address:
(Insert complete mailing address, including country) 117, avenue du Drapeau
21000 DIJON - FRANCE

1 **Typewritten Full Name**
of Fifth Joint Inventor (if any)
Given Name Middle Initial Family Name

2 ****Inventor's Signature:**

3 ****Date of Signature:**
Month Day Year

Residence:
City State or Province Country

Citizenship:

Post Office Address:
(Insert complete mailing address, including country)

****Note to Inventors: Please sign name exactly as it appears and insert the actual date of signing.**

This form may be executed only when attached to the first page of the Declaration and Power of Attorney form of the application to which it pertains.